Despite these compelling clinical studies using a direct and extremely potent inhibitor of the Lp-PLA2 enzyme, these findings contrast with results of several previously published reports that suggest Lp-PLA2 (plasma PAF-AH) activity is inversely associated with disorders in which PAF has been implicated, including asthma (related to overall risk [13], [17] or severity [14], [16]) and anaphylaxis [18]. This evidence concerns the gene PLA2G7 and asthma.